Guggenheim Remains Positive on Valeant (VRX) post Q3: 'In the Kitchen Sink, but Not Down the Drain'
- Wall Street falls as investors ready for Trump's inauguration
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
- Skyworks Solutions (SWKS) Tops Q1 EPS by 3c, Offers Q2 Guidance, Announces Buyback
- After-Hours Stock Movers 01/19: (SWKS) (QRVO) (NVAX) Higher; (AFMD) (SGYP) (IBM) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Guggenheim analyst Louise Chen weighed in on Valeant Pharmaceuticals (NYSE: VRX) after the company reported, as expected, a 3Q16 miss and lowered its '16 EPS guidance.
Chen commented, "VRX has noted since its 1Q16 call that the business should start to recover in 2H16. Evidence of this was demonstrated in 3Q16 as VRX reported sequential improvements in sales and EBITDA throughout the year. Therefore, despite the miss and guide down for '16 and '17, our investment thesis remains intact, and we continue to believe that VRX's growth prospects are underappreciated. Upside could come from: 1) divestment of non-core products to pay down debt; 2) meeting quarterly earnings in '16; and 3) approval and launch of brand drugs."
Positives from 3Q16 call and release that support the firm's thesis:
1) On a sequential basis, sales grew from a base of $2.37B in 1Q16 to $2.42B in 2Q16 to $2.48B in 3Q16.
2) Adjusted EBITDA for 3Q16 came in at $1.16B, an improvement over 2Q16 results of $1.09B and 1Q16 results of $1.01B.
3) Wholesaler inventory levels at Salix were reduced to ~1.5 months as of 9/30/16, consistent with the overall inventory levels for VRX's U.S. products.
4) GAAP CFLO from operations was $570MM vs. $448MM in 2Q16.
5) Dermatology, Ophthalmology, GI and Consumer are four areas that VRX is still committed to growing. The company stated it has received compelling bids for some of these assets and believes that it is VRX's fiduciary duty to evaluate those offers. VRX expects free cash flow and divestitures to go toward $5B of debt paydown by early '18. For context, VRX had $30B of long-term debt as of 9/30/16.
The firm maintained a Buy rating and price target of $55 on VRX.
Shares of Valeant Pharmaceuticals closed at $19.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix (NFLX) PT Raised to $165.00 at Oppenheimer
- Goldman Sachs (GS) PT Raised to $256.00 at Oppenheimer Following 4Q Report
- Stifel Resumes Target (TGT) at Hold
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View
Related EntitiesEarnings, Louise Chen, Guggenheim
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!